Featured Articles

81. Practical Tips To Develop A Lentivirus Packaging Cell Line 9/9/2020

    CAR T therapies are expensive, and lentiviral vectors production represents a large portion of these costs. These practical tips guide efficient development of a lentivirus packaging cell line.

82. 4 Critical Processes Impacting Cost Of Goods For Gene Therapy 8/11/2020

    There is an urgent need to drive down the costs of plasmids and viral vectors. Learn about the critical steps that impact cost and process innovations for viral vector manufacturing.

83. Key Considerations For Cryogenic Preservation And T Cell Viability 7/31/2020

    Illustrating how mammalian cells change when frozen, we offer cryopreservation strategies and identify temperatures at which it's safe to stop controlled cooling and transfer drug product to cryogenic storage.

84. Reducing Cost Of Goods For Gene Therapy 7/24/2020

    Frost & Sullivan's Virtual Think Tank brought together leading minds to discuss key challenges and other insights related to reducing the cost of goods (COGs) for gene therapy.

85. Regulatory Challenges For Viral Vectors For Cell And Gene Therapy 7/24/2020

    Frost & Sullivan's Virtual Think Tank series brought together leading minds in the cell & gene space to discuss current regulatory issues and key challenges in viral vector manufacturing.

86. Developing TIL Therapies: Sample Collection And Processing 7/16/2020

    While it has been advanced over many years, the process of developing TIL therapies still suffers from certain challenges. This article attempts to lay bare some of these challenges and discuss how novel technological solutions can help overcome them.

87. Tumor-Infiltrating Lymphocytes: What, Why, And How 7/1/2020

    As we explore immune mechanisms using technology, we find better ways to fight disease. Here, we focus on targeted, highly personalized cancer therapies called tumor-infiltrating lymphocytes.

88. 6 Misconceptions About Automating Cell Therapy Manufacturing 6/18/2020

    To help you move into a digitized world, here are six common misconceptions that can potentially hinder your ability to successfully execute an MES for cell therapy.

89. Standardizing Vein-To-Vein Logistics To Reach More Patients 2/24/2020

    Collaboration is  key to solving data management and process variability challenges as stakeholders work towards a common goal—getting life-saving treatments to those who need them.

90. LV Scale-Up Workflow In Single-Use Bioreactors For GMP Compliance 11/8/2019

    Cost-effective manufacturing of lentiviral vectors (LV) at commercial scales has proven difficult and remains a pressing issue for the marketing of therapies that depend on their application.